trending Market Intelligence /marketintelligence/en/news-insights/trending/hvpseb_eoprwnaxuauxqda2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Regenxbio plans common stock offering

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

Blog

COVID-19 Impact & Recovery: Investment Banking


Regenxbio plans common stock offering

REGENXBIO Inc., a gene therapy company, plans to sell $175 million of its common stock in an underwritten public offering.

The Rockville, Md.-based company said underwriters will have an option to buy up to an additional 15% of the common shares sold under the offer.

Morgan Stanley, Bank of America Merrill Lynch and Barclays are acting as joint book-running managers. Raymond James is acting as co-manager of the offering.

Regenxbio uses its NAV technology platform, an adeno-associated virus gene delivery platform, to engineer product candidates for treatment of retinal, metabolic and neurodegenerative diseases.